Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Who receives rehabilitation in canadian long-term care facilities? A cross-sectional study.
Vm24, a Natural Immunosuppressant Peptide Potently and Selectively Blocks Kv1.3 Potassium Channels of Human T Cells.
Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis.
[Will multiple sclerosis (MS) susceptibility genes one day become biomarkers for MS diagnosis?]
[Vitamin D and multiple sclerosis : The role for risk of disease and treatment.]
New hope for multiple sclerosis patients.
Pharmacoepidemiology and the Australian regional prevalence of multiple sclerosis.
Devic's disease before Devic: Bilateral optic neuritis and simultaneous myelitis in a young woman (1874).
Primary Cutaneous Cryptococcus in a Patient With Multiple Sclerosis Treated With Fingolimod.
Massage therapy and exercise therapy in patients with multiple sclerosis: a randomized controlled pilot study.
A standardized motor imagery introduction program (MIIP) for neuro-rehabilitation: development and evaluation.
Outcome Measures for Individuals With Multiple Sclerosis: Recommendations From the American Physical Therapy Association Neurology Section Task Force.
Remission with fingolimod in a case of demyelinating polyneuropathy.
Characterization of Oligodendroglial Populations in Mouse Demyelinating Disease Using Flow Cytometry: Clues for MS Pathogenesis.
Use and medicalization of marihuana in cancer patients.
Evaluation of retinal nerve fiber layer thickness measured by optical coherence tomography in Moroccan patients with multiple sclerosis.
Identification of a functional variant in the KIF5A-CYP27B1-METTL1-FAM119B locus associated with multiple sclerosis.
Pediatric Multiple Sclerosis with Primary Progressive Course-Report of a Retrospective Cohort Study in Iran.
Fibronectin aggregation in multiple sclerosis lesions impairs remyelination.
Value of the MoCA Test as a Screening Instrument in Multiple Sclerosis.
Bevacizumab Diminishes Experimental Autoimmune Encephalomyelitis by Inhibiting Spinal Cord Angiogenesis and Reducing Peripheral T-Cell Responses.
Notable Increased Cerebrospinal Fluid Levels of Soluble Interleukin-6 Receptors in Neuromyelitis Optica.
Sphingosine-1-phosphate receptors as emerging targets for treatment of pain.
Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): Extending the spectrum of MOG antibody positive diseases.
Dengue fever in patients with multiple sclerosis taking fingolimod or natalizumab.

Pages